Kidney International® Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis Lupus nephritis is complex and difficult to treat, and clinicians need better tools to understand which patients are most likely to benefit from specific therapies. Using data from the Phase 3 BLISS-LN study, researchers assessed how belimumab affected immune...
The ISN invites applications for editor-in-chief (EIC) of Kidney International Reports®. The EIC will shape the journal’s editorial direction and support the publication of high-quality, clinically relevant kidney research for a global audience. Applications close on July 31, 2026. View the role, criteria, and how to apply
Kidney International® A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy This study tested whether lower-dose prednisolone combined with activated vitamin D could match standard high-dose prednisolone for remission in adults with minimal change disease while reducing steroid toxicity. Although non-inferiority was not formally established, the lower-dose regimen...
The ISN invites applications for editor-in-chief of Kidney International Reports® (KIR). The successful candidate will serve a five-year term (January 2, 2027–December 31, 2031). Applications close on July 31, 2026. Please refer to ISN’s equity, diversity, and inclusion statement. Read the full job description and apply
Kidney International® Conventional cytotoxic chemotherapy–associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup Conventional cytotoxic chemotherapy remains essential in cancer care, but can cause acute and chronic kidney injury. The 34th ADQI Workgroup reviewed the epidemiology, mechanisms, risk factors, clinical manifestations, prevention, and management of nephrotoxicity linked to commonly used agents. The resulting consensus report emphasizes clinician awareness,...
“We are truly a global journal: We do not just select [from] one area that has resources ... authors can submit their papers from whatever region they’re from.” Jai Radhakrishnan As Kidney International Reports® (KIR) marks its 10th anniversary, a WCN'26 Kidney Studio interview with Editor-in-Chief Jai Radhakrishnan reflects on how a bold early commitment to open access and a dedication to...
A new case report in Kidney International Case Reports™ (KICR) describes an exceptionally rare delayed dual invasive fungal infection involving mucormycosis and aspergillosis in the native kidney of a kidney transplant recipient more than 10 years after transplantation. Macroscopic appearance of small whitish tissue (fungal ball) passed in urine The patient presented with fever, right loin...
Kidney International® A population-based,regression discontinuity analysis examined the effects of nationwide alerting for acute kidney injury on health care and patient outcomes This study assessed whether Wales’ nationwide electronic alerts for acute kidney injury (AKI) improved care or patient outcomes in real-world practice. Using a population-based regression discontinuity analysis of hospital and community data from 2016 to...
Kidney International® Tiny warriors, big impact: targeted immunotherapy in kidney diseases This review examines whether emerging B cell-targeting immunotherapies, particularly chimeric antigen receptor T-cell therapy and T-cell engagers, could improve outcomes in autoimmune kidney diseases where current treatments often fail. It summarizes early evidence, mainly from small uncontrolled studies in systemic lupus erythematosus, suggesting these approaches may achieve deeper B-cell depletion...
Jai Radhakrishnan named Editor-in-Chief of Kidney International® May 7, 2026 The International Society of Nephrology (ISN) is pleased to announce the appointment of Jai Radhakrishnan, MD, as the next Editor-in-Chief of Kidney International® (KI), the Society’s flagship journal. His term will begin on January 1, 2027, succeeding Pierre Ronco, MD, PhD. Dr. Radhakrishnan is a Professor of...
From unusual presentations and diagnostic dilemmas to novel treatment approaches, the first in press case reports featured in Kidney International Case Reports™ (KICR) highlight clinically relevant lessons from real-world kidney care across diverse global settings. Explore the first edition Among the early reports are cases that underline how rapidly evolving therapies are reshaping practice. Al Haddad...
Kidney International® A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy This study addressed how to better target corticosteroid treatment in IgA nephropathy, (IgAN) where benefits must be weighed against important side effects. Using a secondary analysis of the TESTING trial, the authors developed a model to predict each patient’s likely response to...
Ten years ago, Kidney International Reports® (KIR) launched with a clear mission: to expand access to high-quality kidney research and ensure that important discoveries reach clinicians, researchers, and health systems worldwide. Over the past decade, the journal has published studies that have shaped care and policy, fostered opportunities for early-career researchers to contribute and collaborate, and elevated voices...
NephJC has extended the conversation around WCN’26 late-breaking trials with expert commentary on selected studies presented in Yokohama, including the ASSIST trial, 24-month data from APPLAUSE-IGAN, and new analyses from the CONFIDENCE trial. Read the commentaries A video interview recorded onsite at WCN’26 in Yokohama features NephJC Founding Editor-in-Chief Swapnil Hiremath and Managing Editor Cristina Popa discussing selected late-breaking...
Kidney International® Uremia and parathyroid hormone have distinct effects on bone protein and gene expression People with chronic kidney disease (CKD) remain at high risk of fractures despite treatment aimed at maintaining parathyroid hormone at acceptable levels. This study examined the distinct effects of uremia and parathyroid hormone on bone in patients on hemodialysis and controls. The authors...
Kidney International® Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors This mini review examines infection prevention in patients receiving novel complement inhibitors, with a focus on serious infections caused by encapsulated organisms. It outlines practical strategies, including vaccination, antibiotic prophylaxis, and patient education. The authors stress that these therapies offer important benefits...
Kidney International® A single-arm phase 2 trial of an investigational RNA therapeutic targeting complement factor B (sefaxersen) for treatment of IgA nephropathy IgA nephropathy (IgAN) involves activation of the complement alternative pathway, contributing to kidney inflammation and disease progression. In this global, open-label phase 2 trial, patients with biopsy-confirmed IgAN received sefaxersen, an antisense inhibitor of complement factor B, to...
Every nephrologist has encountered a case that stayed with them, one that challenged assumptions, raised new questions, or changed how they approach care. Turning that experience into a case report is not about including every detail, but about sharing the clinical lesson that others can apply. Submit your case report to KICR Kidney International Case Reports™...
Kidney International® A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease This randomized, double-blind trial evaluated whether pravastatin could slow disease progression in adults with early autosomal dominant polycystic kidney disease (ADPKD) and preserved kidney function. Researchers followed 150 participants receiving pravastatin or a placebo...
Who can access the evidence that informs practice, and how quickly does that evidence reach the bedside? As Kidney International Reports® (KIR) celebrates its 10th anniversary throughout 2026, these two questions are as pertinent as ever for clinicians and researchers working in kidney care. Reflections from KIR’s Editor-in-Chief Jai Radhakrishnan and Deputy Editor Sumit Mohan highlight how the journal’s editorial decisions, including a commitment to open access and a focus on practice-relevant research, have supported wider access...
